Abstract
Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Current HIV Research
Title: Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates.
Volume: 5 Issue: 2
Author(s): Radmila Metlas, Tanja Srdic and Veljko Veljkovic
Affiliation:
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Abstract: Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Export Options
About this article
Cite this article as:
Metlas Radmila, Srdic Tanja and Veljkovic Veljko, Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates., Current HIV Research 2007; 5 (2) . https://dx.doi.org/10.2174/157016207780077093
DOI https://dx.doi.org/10.2174/157016207780077093 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer
Current Gene Therapy Urocortins: Take Them to Heart
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Conventional and Alternative Treatment Options for Allergic Rhinitis
Current Respiratory Medicine Reviews New Insights into the Regulation of Liver Inflammation and Oxidative Stress
Mini-Reviews in Medicinal Chemistry Inflammatory Modulation of Hepatocyte Apoptosis by Nitric Oxide: In Vivo, In Vitro, and In Silico Studies
Current Molecular Medicine Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a ‘New Frontier’?
Anti-Cancer Agents in Medicinal Chemistry Blood-Brain Barrier and Feeding: Regulatory Roles of Saturable Transport Systems for Ingestive Peptides
Current Pharmaceutical Design Medial Vascular Calcification in Diabetes Mellitus and Chronic Kidney Disease: The Role of Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Lipophilicity and Other Parameters Affecting Brain Penetration
Current Medicinal Chemistry - Central Nervous System Agents Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Picornavirus IRES: Structure Function Relationship
Current Pharmaceutical Design Synthesis and Biological Evaluation of Berberine Derivatives as IBS Modulator
Letters in Drug Design & Discovery Macrophages in Inflammation
Current Drug Targets - Inflammation & Allergy Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine Hydrogen Sulfide-Based Anti-Inflammatory and Chemopreventive Therapies: An Experimental Approach
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design Editorial [ Pharmacological Modulation of Liver Ischemia - Reperfusion Injury Executive Editors: G.K. Glantzounis, D.P. Mikhailidis, A.M. Seifalian and B.R. Davidson ]
Current Pharmaceutical Design Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Tissue Injury and Related Mediators of Pain Exacerbation
Current Neuropharmacology